Zacks Small Cap Comments on CEL-SCI Co.’s FY2024 Earnings (NYSE:CVM)

CEL-SCI Co. (NYSE:CVM) – Equities researchers at Zacks Small Cap lowered their FY2024 earnings per share estimates for shares of CEL-SCI in a research report issued on Monday, April 15th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will post earnings per share of ($0.51) for the year, down from their prior estimate of ($0.48). The consensus estimate for CEL-SCI’s current full-year earnings is ($0.48) per share.

Separately, StockNews.com cut CEL-SCI from a “hold” rating to a “sell” rating in a report on Friday, March 15th.

CEL-SCI Price Performance

Shares of CVM stock opened at $1.50 on Wednesday. The stock has a 50 day moving average of $2.03 and a two-hundred day moving average of $2.18. The company has a current ratio of 1.26, a quick ratio of 0.78 and a debt-to-equity ratio of 0.75. CEL-SCI has a 12 month low of $1.04 and a 12 month high of $3.23. The company has a market capitalization of $80.97 million, a P/E ratio of -2.21 and a beta of 1.29.

CEL-SCI (NYSE:CVM) last announced its quarterly earnings data on Wednesday, February 14th. The company reported ($0.14) EPS for the quarter.

Hedge Funds Weigh In On CEL-SCI

A number of hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD raised its holdings in shares of CEL-SCI by 23.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 19,800 shares of the company’s stock worth $89,000 after buying an additional 3,823 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of CEL-SCI by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 382,101 shares of the company’s stock worth $897,000 after buying an additional 4,046 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of CEL-SCI by 195.1% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 8,280 shares of the company’s stock worth $37,000 after buying an additional 5,474 shares in the last quarter. Northern Trust Corp increased its holdings in CEL-SCI by 7.2% during the 4th quarter. Northern Trust Corp now owns 83,864 shares of the company’s stock valued at $228,000 after purchasing an additional 5,629 shares in the last quarter. Finally, Swiss National Bank increased its holdings in CEL-SCI by 7.4% during the 1st quarter. Swiss National Bank now owns 101,700 shares of the company’s stock valued at $400,000 after purchasing an additional 7,000 shares in the last quarter. 12.08% of the stock is owned by institutional investors and hedge funds.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.